NGEN · Insider Trading
NervGen Pharma Corp. Common stock
Every open-market purchase and sale reported by NGEN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2009-01-21 | David Ludvigson | President & COO | Buy | +1,666 | +$198 |
| 2009-01-21 | Nicholas J. Venuto | VP, Chief Financial Officer | Buy | +1,666 | +$198 |
| 2009-01-21 | Graham Peter Lidgard | Sr. VP R&D, CTO | Buy | +1,666 | +$198 |
| 2008-07-03 | Graham Peter Lidgard | Sr. VP R&D, CTO | Buy | +1,666 | +$510 |
| 2008-07-03 | David Ludvigson | President & COO | Buy | +1,666 | +$510 |
| 2008-07-03 | Nicholas J. Venuto | VP, Chief Financial Officer | Buy | +1,666 | +$510 |
| 2008-07-01 | Heiner Dreismann | Director | A | +59,524 | — |
| 2008-07-01 | Stelios B Papadopoulos | Director | A | +59,524 | — |
| 2008-07-01 | Robert E Whalen | Director | A | +59,524 | — |
| 2008-07-01 | David Schreiber | Director | A | +59,524 | — |
| 2008-04-23 | William L Respess | Sr. VP, General Counsel & Sec | A | +187,500 deriv. | — |
| 2008-04-23 | Graham Peter Lidgard | Sr. VP R&D, CTO | A | +187,500 deriv. | — |
| 2008-04-23 | Howard C Birndorf | Executive Chairman and CEO | A | +547,500 deriv. | — |
| 2008-04-23 | David Ludvigson | President & COO | A | +300,000 deriv. | — |
| 2008-04-23 | Nicholas J. Venuto | VP, Chief Financial Officer | A | −187,500 deriv. | — |
| 2008-04-16 | William L Respess | Sr. VP, General Counsel & Sec | A | +27,606 | +$11.48K |
| 2007-06-15 | Heiner Dreismann | Director | A | +18,116 | — |
| 2007-06-15 | Graham Peter Lidgard | Sr. VP R&D, CTO | A | +187,500 deriv. | — |
| 2007-06-15 | Stelios B Papadopoulos | Director | A | +18,116 | — |
| 2007-06-15 | Howard C Birndorf | Executive Chairman and CEO | A | +547,500 deriv. | — |
| 2007-06-15 | David Schreiber | Director | A | +18,116 | — |
| 2007-06-15 | David Ludvigson | President & COO | A | +300,000 deriv. | — |
| 2007-06-15 | Robert Saltmarsh | VP, Chief Financial Officer | A | +187,500 deriv. | — |
| 2007-06-15 | William L Respess | Sr. VP, General Counsel & Sec | A | +187,500 deriv. | — |
| 2007-06-15 | Robert E Whalen | Director | A | +18,116 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NGEN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.